Evaluation of Antiemetic Therapy for Hepatic Transcatheter Arterial Infusion Chemotherapy with Cisplatin

• Published in: Biological and Pharmaceutical Bulletin Vol. 39; no. 4; pp. 611 - 614
• Main Authors: Junya Hashizume, Norihide Higuchi, Kayoko Sato, Yukinobu Kodama, Noriko Matsunaga, Toshiaki Sakamoto, Kentaro Yamaguchi, Tadahiro Nakamura, Takashi Kitahara, Hitoshi Sasaki
• Format: Journal Article
• Language: Japanese
• Published: Pharmaceutical Society of Japan 01.04.2016
• ISSN: 0918-6158; 1347-5215

Antiemetic prophylaxis with aprepitant, a 5-hydroxytryptamine3 (5-HT3) receptor antagonist and dexamethasone is recommended for patients receiving intravenous cisplatin chemotherapy. Whether the same antiemetic regime is superior for hepatic transcatheter arterial infusion chemotherapy with cisplatin (CDDP-TAI) is unknown. We conducted a retrospective study of antiemetic prophylaxis protection against chemotherapy-induced nausea and vomiting (CINV) in CDDP-TAI at Nagasaki University Hospital. The rate of complete response (CR) to antiemetics in the acute (<24h) and delayed phases (24-120h) was measured. Twenty-four patients were treated with a 5-HT3 receptor antagonist (granisetron or azasetron) and dexamethasone on the day of chemotherapy (day 1 only). There was a significant difference between the CR rates in the acute and delayed phases, 91.6, and 69.7%, respectively. Combination of a 5-HT, antagonist and dexamethasone on day 1 is effective against acute CINV, but not delayed CINV during CDDP-TAI. These results may help guide the management of nausea and vomiting during CDDP-TAI to achieve better tolerance and compliance for fewer interventions and increased favorable therapeutic outcomes.